HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $25 price target.
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ:AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl)…